Share Price and Basic Stock Data
Last Updated: December 24, 2025, 9:21 pm
| PEG Ratio | -2.98 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Lasa Supergenerics Ltd operates within the specialty chemicals sector, focusing on a niche market. As of the latest reporting, the company’s stock price stood at ₹9.38, with a market capitalization of ₹46.9 Cr. Over the past several quarters, Lasa’s sales demonstrated volatility, peaking at ₹35 lakh in March 2023, before declining to ₹24 lakh in September 2023. However, sales rebounded to ₹27 lakh in December 2023. A comparison of annual sales reveals a downward trend from ₹137 Cr in March 2022 to ₹130 Cr in March 2023, continuing to ₹104 Cr in March 2024. This decline in revenue reflects broader challenges faced by the company in maintaining growth in a competitive environment. The trailing twelve months (TTM) revenue was reported at ₹95 Cr, indicating ongoing difficulties in achieving consistent sales performance.
Profitability and Efficiency Metrics
The profitability of Lasa Supergenerics Ltd has been under significant pressure, with the company reporting a net loss of ₹36 lakh for the latest fiscal year. This represents a stark contrast to the profitability observed in previous years, where net profit was recorded at ₹23 lakh in March 2021. The operating profit margin (OPM) stood at -2% for the current period, reflecting operational inefficiencies that have persisted over time. The interest coverage ratio (ICR) is relatively strong at 4.19x, indicating the company’s ability to meet its interest obligations despite the losses. However, the return on equity (ROE) and return on capital employed (ROCE) are both severely low at 1.01% and 1.00%, respectively, highlighting the inefficiencies in capital utilization. These figures suggest that while the company manages its debt well, it struggles to convert sales into profits effectively.
Balance Sheet Strength and Financial Ratios
Lasa Supergenerics Ltd’s balance sheet reveals a concerning financial position, with total liabilities amounting to ₹102 Cr against total assets of ₹102 Cr as of March 2025. The company has reserves of ₹6 Cr, which provide some cushion against operational losses. Borrowings are reported at ₹7 Cr, indicating a manageable level of debt. The current ratio improved to 1.90, suggesting that the company can cover its short-term obligations, although the quick ratio of 0.46 indicates potential liquidity issues. The price-to-book value (P/BV) ratio stands at 1.01x, suggesting that the stock is fairly valued relative to its book value. However, the decline in book value per share from ₹39.07 in March 2021 to ₹16.71 in March 2025 raises concerns about the company’s long-term financial health and ability to recover from its current challenges.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Lasa Supergenerics Ltd shows a significant promoter ownership of 53.65%, indicating a strong level of control by the founding members. The public holds 46.35% of the shares, reflecting a fairly balanced distribution between promoters and the public. Notably, foreign institutional investors (FIIs) have shown little interest, maintaining a 0.00% stake. Over time, the number of shareholders has declined from 28,936 in December 2022 to 28,656 as of September 2025, which may indicate waning investor confidence. The lack of dividend payouts in recent years, with a payout of ₹0.25 only in 2021, further complicates the attractiveness of the stock for potential investors. This shareholding structure and the lack of institutional interest may hinder the ability of the company to attract additional investments, crucial for operational improvements.
Outlook, Risks, and Final Insight
The outlook for Lasa Supergenerics Ltd remains challenging given its current financial metrics and operational performance. Key risks include ongoing operational inefficiencies, as evidenced by consistently negative profit margins, and a declining sales trajectory, which could further erode investor confidence. Additionally, the company’s heavy reliance on promoter support may stifle the diversity of thought required for strategic pivots in a competitive market. Conversely, the strong interest coverage ratio reflects a capacity to manage debt, and the high promoter stake may provide stability during tumultuous periods. Should the company implement effective cost-control measures and enhance its operational efficiencies, there is potential for recovery. However, without significant changes, the risk of continued financial underperformance looms large, necessitating close monitoring by stakeholders.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 409 Cr. | 43.5 | 83.5/41.2 | 25.4 | 20.5 | 0.92 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 31.2 Cr. | 63.5 | 91.9/56.0 | 14.9 | 89.6 | 1.57 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 49.6 Cr. | 730 | 935/600 | 22.9 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,406 Cr. | 75.1 | 111/74.0 | 22.6 | 22.0 | 0.67 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 651 Cr. | 261 | 393/241 | 23.4 | 93.8 | 0.96 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,790.80 Cr | 727.35 | 71.44 | 183.02 | 0.44% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 34 | 32 | 35 | 31 | 24 | 27 | 23 | 31 | 39 | 33 | 39 | 20 |
| Expenses | 37 | 34 | 34 | 31 | 27 | 23 | 26 | 27 | 29 | 39 | 33 | 36 | 21 |
| Operating Profit | -8 | -0 | -2 | 4 | 4 | 1 | 1 | -4 | 2 | 1 | 0 | 3 | -0 |
| OPM % | -28% | -1% | -8% | 12% | 13% | 4% | 4% | -17% | 6% | 2% | 1% | 9% | -2% |
| Other Income | 0 | -2 | 1 | -19 | 0 | 0 | 0 | -9 | 0 | 2 | 9 | -22 | -20 |
| Interest | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 2 |
| Profit before tax | -11 | -7 | -5 | -19 | 1 | -2 | -2 | -16 | -2 | -1 | 6 | -22 | -23 |
| Tax % | 8% | -2% | -4% | -22% | 581% | -99% | -30% | -4% | 47% | 147% | 7% | -35% | -6% |
| Net Profit | -12 | -7 | -5 | -15 | -5 | -0 | -1 | -15 | -3 | -3 | 5 | -14 | -21 |
| EPS in Rs | -2.97 | -1.63 | -1.21 | -2.99 | -0.99 | -0.00 | -0.29 | -3.05 | -0.54 | -0.64 | 1.10 | -2.85 | -4.22 |
Last Updated: August 20, 2025, 7:50 am
Below is a detailed analysis of the quarterly data for Lasa Supergenerics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 19.00 Cr..
- For Expenses, as of Jun 2025, the value is 21.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 36.00 Cr. (Mar 2025) to 21.00 Cr., marking a decrease of 15.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 3.00 Cr..
- For OPM %, as of Jun 2025, the value is -2.00%. The value appears to be declining and may need further review. It has decreased from 9.00% (Mar 2025) to -2.00%, marking a decrease of 11.00%.
- For Other Income, as of Jun 2025, the value is -20.00 Cr.. The value appears strong and on an upward trend. It has increased from -22.00 Cr. (Mar 2025) to -20.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -23.00 Cr.. The value appears to be declining and may need further review. It has decreased from -22.00 Cr. (Mar 2025) to -23.00 Cr., marking a decrease of 1.00 Cr..
- For Tax %, as of Jun 2025, the value is -6.00%. The value appears to be increasing, which may not be favorable. It has increased from -35.00% (Mar 2025) to -6.00%, marking an increase of 29.00%.
- For Net Profit, as of Jun 2025, the value is -21.00 Cr.. The value appears to be declining and may need further review. It has decreased from -14.00 Cr. (Mar 2025) to -21.00 Cr., marking a decrease of 7.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -4.22. The value appears to be declining and may need further review. It has decreased from -2.85 (Mar 2025) to -4.22, marking a decrease of 1.37.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:03 am
| Metric | Mar 2016n n 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 199 | 244 | 170 | 167 | 201 | 137 | 130 | 104 | 142 | 95 |
| Expenses | 0 | 153 | 202 | 158 | 137 | 154 | 120 | 136 | 102 | 136 | 96 |
| Operating Profit | 0 | 46 | 41 | 11 | 30 | 47 | 16 | -6 | 2 | 6 | -1 |
| OPM % | 23% | 17% | 7% | 18% | 24% | 12% | -5% | 2% | 4% | -1% | |
| Other Income | 0 | -24 | 3 | 0 | 0 | 0 | -8 | -18 | -9 | -11 | -33 |
| Interest | 0 | 12 | 11 | 8 | 8 | 2 | 0 | 4 | 2 | 3 | 1 |
| Depreciation | 0 | 8 | 18 | 19 | 17 | 16 | 15 | 13 | 11 | 12 | 10 |
| Profit before tax | 0 | 2 | 15 | -16 | 5 | 30 | -6 | -42 | -19 | -19 | -44 |
| Tax % | -10% | 19% | -25% | 23% | 23% | -13% | -9% | 14% | -24% | ||
| Net Profit | 0 | 2 | 12 | -12 | 4 | 23 | -5 | -39 | -22 | -15 | -36 |
| EPS in Rs | 5.40 | -5.26 | 0.89 | 5.60 | -1.31 | -7.71 | -4.34 | -2.95 | -7.22 | ||
| Dividend Payout % | 0% | 0% | 0% | 0% | 4% | -24% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 500.00% | -200.00% | 133.33% | 475.00% | -121.74% | -680.00% | 43.59% | 31.82% |
| Change in YoY Net Profit Growth (%) | 0.00% | -700.00% | 333.33% | 341.67% | -596.74% | -558.26% | 723.59% | -11.77% |
Lasa Supergenerics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | 1% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -25% |
| 3 Years: | -28% |
| TTM: | 133% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -32% |
| 3 Years: | -38% |
| 1 Year: | -73% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -10% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 9:35 am
Balance Sheet
Last Updated: December 4, 2025, 1:33 am
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 23 | 23 | 41 | 41 | 50 | 50 | 50 | 50 | 50 |
| Reserves | 0 | 75 | 94 | 82 | 101 | 118 | 108 | 68 | 47 | 34 | 6 |
| Borrowings | 0 | 116 | 107 | 85 | 48 | 19 | 20 | 22 | 22 | 2 | 7 |
| Other Liabilities | 0 | 37 | 63 | 69 | 42 | 29 | 31 | 24 | 32 | 16 | 8 |
| Total Liabilities | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 72 |
| Fixed Assets | 0 | 119 | 170 | 162 | 152 | 143 | 137 | 119 | 110 | 68 | 58 |
| CWIP | 0 | 30 | 7 | 7 | 0 | 0 | 5 | 5 | 3 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 80 | 110 | 90 | 80 | 65 | 67 | 40 | 39 | 33 | 13 |
| Total Assets | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 72 |
Below is a detailed analysis of the balance sheet data for Lasa Supergenerics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 50.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 50.00 Cr..
- For Reserves, as of Sep 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 34.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 28.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 2.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 8.00 Cr.. The value appears to be improving (decreasing). It has decreased from 16.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 72.00 Cr.. The value appears to be improving (decreasing). It has decreased from 102.00 Cr. (Mar 2025) to 72.00 Cr., marking a decrease of 30.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 68.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 10.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 13.00 Cr., marking a decrease of 20.00 Cr..
- For Total Assets, as of Sep 2025, the value is 72.00 Cr.. The value appears to be declining and may need further review. It has decreased from 102.00 Cr. (Mar 2025) to 72.00 Cr., marking a decrease of 30.00 Cr..
However, the Borrowings (7.00 Cr.) are higher than the Reserves (6.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2016n n 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | -70.00 | -66.00 | -74.00 | -18.00 | 28.00 | -4.00 | -28.00 | -20.00 | 4.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 63 | 62 | 45 | 27 | 50 | 7 | 13 | 4 | |
| Inventory Days | 93 | 90 | 90 | 101 | 56 | 46 | 48 | 92 | 84 | |
| Days Payable | 71 | 102 | 170 | 130 | 41 | 68 | 32 | 68 | 35 | |
| Cash Conversion Cycle | 87 | 51 | -18 | 16 | 42 | 28 | 22 | 37 | 53 | |
| Working Capital Days | 15 | -1 | -52 | -13 | 35 | 12 | -17 | -44 | 37 | |
| ROCE % | 42% | 13% | -4% | 7% | 17% | 1% | -12% | -6% | -1% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -2.95 | -4.34 | -7.71 | -1.30 | 5.60 |
| Diluted EPS (Rs.) | -2.95 | -4.34 | -7.71 | -1.30 | 5.60 |
| Cash EPS (Rs.) | -0.49 | -2.21 | -5.03 | 2.12 | 9.49 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 16.71 | 19.30 | 23.61 | 36.54 | 39.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 16.71 | 19.30 | 23.61 | 36.54 | 39.07 |
| Dividend / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.25 | 0.25 |
| Revenue From Operations / Share (Rs.) | 28.43 | 20.82 | 25.86 | 33.71 | 49.76 |
| PBDIT / Share (Rs.) | 2.25 | 0.45 | -0.95 | 3.86 | 11.62 |
| PBIT / Share (Rs.) | -0.20 | -1.68 | -3.63 | 0.41 | 7.73 |
| PBT / Share (Rs.) | -3.87 | -3.81 | -8.44 | -1.53 | 7.25 |
| Net Profit / Share (Rs.) | -2.94 | -4.34 | -7.71 | -1.32 | 5.60 |
| PBDIT Margin (%) | 7.91 | 2.17 | -3.69 | 11.44 | 23.36 |
| PBIT Margin (%) | -0.71 | -8.05 | -14.05 | 1.23 | 15.54 |
| PBT Margin (%) | -13.60 | -18.31 | -32.62 | -4.52 | 14.57 |
| Net Profit Margin (%) | -10.35 | -20.82 | -29.80 | -3.91 | 11.25 |
| Return on Networth / Equity (%) | -17.62 | -22.47 | -32.65 | -3.61 | 14.33 |
| Return on Capital Employeed (%) | -1.21 | -8.24 | -15.03 | 1.08 | 18.79 |
| Return On Assets (%) | -14.53 | -14.40 | -23.57 | -2.69 | 10.95 |
| Asset Turnover Ratio (%) | 1.13 | 0.66 | 0.71 | 0.67 | 0.92 |
| Current Ratio (X) | 1.90 | 0.77 | 0.91 | 1.65 | 1.59 |
| Quick Ratio (X) | 0.46 | 0.38 | 0.59 | 1.39 | 1.16 |
| Inventory Turnover Ratio (X) | 6.54 | 4.81 | 8.67 | 6.13 | 4.69 |
| Interest Coverage Ratio (X) | 4.19 | 1.17 | -1.15 | 389.33 | 24.08 |
| Interest Coverage Ratio (Post Tax) (X) | 1.34 | -5.71 | -3.50 | 62.86 | 12.60 |
| Enterprise Value (Cr.) | 83.63 | 108.58 | 90.15 | 152.41 | 239.23 |
| EV / Net Operating Revenue (X) | 0.58 | 1.04 | 0.69 | 1.11 | 1.18 |
| EV / EBITDA (X) | 7.42 | 47.93 | -18.82 | 9.71 | 5.06 |
| MarketCap / Net Operating Revenue (X) | 0.59 | 1.05 | 0.71 | 1.24 | 1.20 |
| Price / BV (X) | 1.01 | 1.14 | 0.78 | 1.14 | 1.53 |
| Price / Net Operating Revenue (X) | 0.59 | 1.05 | 0.71 | 1.24 | 1.20 |
| EarningsYield | -0.17 | -0.19 | -0.41 | -0.03 | 0.09 |
After reviewing the key financial ratios for Lasa Supergenerics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -2.95. This value is below the healthy minimum of 5. It has increased from -4.34 (Mar 24) to -2.95, marking an increase of 1.39.
- For Diluted EPS (Rs.), as of Mar 25, the value is -2.95. This value is below the healthy minimum of 5. It has increased from -4.34 (Mar 24) to -2.95, marking an increase of 1.39.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.49. This value is below the healthy minimum of 3. It has increased from -2.21 (Mar 24) to -0.49, marking an increase of 1.72.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.71. It has decreased from 19.30 (Mar 24) to 16.71, marking a decrease of 2.59.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.71. It has decreased from 19.30 (Mar 24) to 16.71, marking a decrease of 2.59.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 28.43. It has increased from 20.82 (Mar 24) to 28.43, marking an increase of 7.61.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.25. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 2.25, marking an increase of 1.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.20. This value is below the healthy minimum of 0. It has increased from -1.68 (Mar 24) to -0.20, marking an increase of 1.48.
- For PBT / Share (Rs.), as of Mar 25, the value is -3.87. This value is below the healthy minimum of 0. It has decreased from -3.81 (Mar 24) to -3.87, marking a decrease of 0.06.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -2.94. This value is below the healthy minimum of 2. It has increased from -4.34 (Mar 24) to -2.94, marking an increase of 1.40.
- For PBDIT Margin (%), as of Mar 25, the value is 7.91. This value is below the healthy minimum of 10. It has increased from 2.17 (Mar 24) to 7.91, marking an increase of 5.74.
- For PBIT Margin (%), as of Mar 25, the value is -0.71. This value is below the healthy minimum of 10. It has increased from -8.05 (Mar 24) to -0.71, marking an increase of 7.34.
- For PBT Margin (%), as of Mar 25, the value is -13.60. This value is below the healthy minimum of 10. It has increased from -18.31 (Mar 24) to -13.60, marking an increase of 4.71.
- For Net Profit Margin (%), as of Mar 25, the value is -10.35. This value is below the healthy minimum of 5. It has increased from -20.82 (Mar 24) to -10.35, marking an increase of 10.47.
- For Return on Networth / Equity (%), as of Mar 25, the value is -17.62. This value is below the healthy minimum of 15. It has increased from -22.47 (Mar 24) to -17.62, marking an increase of 4.85.
- For Return on Capital Employeed (%), as of Mar 25, the value is -1.21. This value is below the healthy minimum of 10. It has increased from -8.24 (Mar 24) to -1.21, marking an increase of 7.03.
- For Return On Assets (%), as of Mar 25, the value is -14.53. This value is below the healthy minimum of 5. It has decreased from -14.40 (Mar 24) to -14.53, marking a decrease of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.13. It has increased from 0.66 (Mar 24) to 1.13, marking an increase of 0.47.
- For Current Ratio (X), as of Mar 25, the value is 1.90. This value is within the healthy range. It has increased from 0.77 (Mar 24) to 1.90, marking an increase of 1.13.
- For Quick Ratio (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.38 (Mar 24) to 0.46, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.54. This value is within the healthy range. It has increased from 4.81 (Mar 24) to 6.54, marking an increase of 1.73.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.19. This value is within the healthy range. It has increased from 1.17 (Mar 24) to 4.19, marking an increase of 3.02.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.34. This value is below the healthy minimum of 3. It has increased from -5.71 (Mar 24) to 1.34, marking an increase of 7.05.
- For Enterprise Value (Cr.), as of Mar 25, the value is 83.63. It has decreased from 108.58 (Mar 24) to 83.63, marking a decrease of 24.95.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1. It has decreased from 1.04 (Mar 24) to 0.58, marking a decrease of 0.46.
- For EV / EBITDA (X), as of Mar 25, the value is 7.42. This value is within the healthy range. It has decreased from 47.93 (Mar 24) to 7.42, marking a decrease of 40.51.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.05 (Mar 24) to 0.59, marking a decrease of 0.46.
- For Price / BV (X), as of Mar 25, the value is 1.01. This value is within the healthy range. It has decreased from 1.14 (Mar 24) to 1.01, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.05 (Mar 24) to 0.59, marking a decrease of 0.46.
- For EarningsYield, as of Mar 25, the value is -0.17. This value is below the healthy minimum of 5. It has increased from -0.19 (Mar 24) to -0.17, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lasa Supergenerics Ltd:
- Net Profit Margin: -10.35%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -1.21% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -17.62% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.34
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 95.7 (Industry average Stock P/E: 71.44)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -10.35%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Plot No C-4, C-4/1, MIDC, Lote Parshuram Industrial Area, Ratnagiri Dist. Maharashtra 415722 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Omkar Pravin Herlekar | Chairman & Managing Director |
| Mr. Prathamesh Chalke | Whole Time Director |
| Mr. Ketan Bhau Songal | Independent Director |
| Mr. Pravin Gadalya Lachake | Independent Director |
| Mr. Yogesh Hari Ughada | Independent Director |
| Mrs. Rekha Hemant Wakh | Independent Director |
FAQ
What is the intrinsic value of Lasa Supergenerics Ltd?
Lasa Supergenerics Ltd's intrinsic value (as of 24 December 2025) is 8.83 which is 3.92% lower the current market price of 9.19, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 45.9 Cr. market cap, FY2025-2026 high/low of 31.4/8.16, reserves of ₹6 Cr, and liabilities of 72 Cr.
What is the Market Cap of Lasa Supergenerics Ltd?
The Market Cap of Lasa Supergenerics Ltd is 45.9 Cr..
What is the current Stock Price of Lasa Supergenerics Ltd as on 24 December 2025?
The current stock price of Lasa Supergenerics Ltd as on 24 December 2025 is 9.19.
What is the High / Low of Lasa Supergenerics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lasa Supergenerics Ltd stocks is 31.4/8.16.
What is the Stock P/E of Lasa Supergenerics Ltd?
The Stock P/E of Lasa Supergenerics Ltd is 95.7.
What is the Book Value of Lasa Supergenerics Ltd?
The Book Value of Lasa Supergenerics Ltd is 11.2.
What is the Dividend Yield of Lasa Supergenerics Ltd?
The Dividend Yield of Lasa Supergenerics Ltd is 0.00 %.
What is the ROCE of Lasa Supergenerics Ltd?
The ROCE of Lasa Supergenerics Ltd is 1.00 %.
What is the ROE of Lasa Supergenerics Ltd?
The ROE of Lasa Supergenerics Ltd is 1.01 %.
What is the Face Value of Lasa Supergenerics Ltd?
The Face Value of Lasa Supergenerics Ltd is 10.0.